
Loading, please wait...

Loading, please wait...

China's drug regulator recently announced a landmark decision regarding neural technology. They granted the world's first commercial BCI medical device approval. This innovative system helps patients with quadriplegia regain hand-grasping abilities. Borui Kang Medical Technology developed this invasive device. It uses electrodes placed directly onto the brain via minimally invasive extradural implantation.
The approval marks a significant shift in global neuro-technology regulation. Doctors can now offer this advanced wireless technology to eligible patients. Consequently, individuals with cervical spinal cord injuries may see a vastly improved quality of life. The system specifically targets adults between 18 and 60 years old. Furthermore, patients must have a stable condition for at least six months post-injury. This stability ensures the safest and most effective outcomes during the recovery phase.
Eligible candidates for the device must demonstrate a total lack of hand-grasping function. However, they must still retain some residual upper-arm movement. Additionally, clinical trials showed significant gains in motor control among participants. Therefore, the National Medical Products Administration has prioritized the development of these sectors. Beijing officially designated brain-computer interfaces as a core future industry in its latest plan. Experts believe BCI technology will move into practical public use within five years. As a result, this approval sets a historic global regulatory precedent for neuro-prosthetics.
Q1: Who is eligible for this new BCI treatment?
Patients aged 18 to 60 with cervical spinal cord injuries leading to quadriplegia are the primary candidates for this device.
Q2: How does the invasive BCI system function?
The device uses minimally invasive extradural electrodes and wireless technology to record brain signals and translate them into physical hand movements.
Q3: What are the clinical requirements before implantation?
The diagnosis must be at least one year old, and the patient must have been in a stable condition for six months following standard treatment.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


China’s drug regulator has approved the world’s first commercial brain-computer interface (BCI) system to restore hand-grasping ability in paralyzed patient...
7 months ago

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

Recent clinical studies reveal maternal autoantibodies targeting IL-1RA as potential triggers for preterm labor, opening avenues for targeted cytokine therapies. Concurrently, new perioperative findings show inhaled cannabis increases propofol requirements during upper endoscopy compared to oral edible consumption.
Today

In high-risk pulmonary embolism complicated by severe anemia and active uterine bleeding, systemic thrombolysis is contraindicated. Large-bore aspiration thrombectomy provides rapid hemodynamic rescue without fibrinolysis, supported by inferior vena cava filter placement and multidisciplinary critical care.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today